방사선의학 웹진

바로가기  >

Abstract
Transformed small-cell lung cancer (tSCLC) from EGFR-mutant adenocarcinoma is a rare and aggressive form of lung cancer that can occur when the tumor develops resistance to EGFR targeted therapy and the cancer cells acquire additional genomic alterations that cause them to transform into SCLC. Treatment for tSCLC has not been established yet, and chemotherapy regimens for de novo SCLC are mostly recommended. However, these treatments showed disappointing outcome, and novel anti-cancer agents and immunological approaches are currently being developed. The patient-derived cell line is a critical tool for pre-clinical and translational research, but cell line models for tSCLC are not publicly available from cell banks. The aim of this study was to establish and characterize a novel cell line for tSCLC. Using a lymph-node biopsy tissue from a 58-year-old female patient, whose tumor was EGFR-mutant lung adenocarcinoma progressed on afatinib, we successfully established a cell line, named BMC-PDC-019. The tumor sample and cell line showed a typical expression of SCLC markers, such as CD56 and synaptophysin. The population doubling-time of BMC-PDC-019 cells was 48 h. We examined a range of proliferation-inhibiting effects of anti-cancer drugs currently used for de novo SCLC, using BMC-PDC-019 cells. We concluded that BMC-PDC-019 would be a useful tool for pre-clinical and translational research.

Affiliations

Mi Young Kim 1, Seung Yeon Jung 1, Sungyoul Hong 2, So Won Oh 3, Kwang Nam Jin 4, Ji Eun Kim 5, Jin-Soo Kim 6
1Department of Internal Medicine, Seoul National University Boramae Medical Center, 20 Boramae-Ro-5-Gil, Dongjak-Gu, Seoul, 07061, Republic of Korea.
2Seoul National University College of Pharmacy, Seoul, Republic of Korea.
3Department of Nuclear Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
4Department of Radiology, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
5Department of Pathology, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
6Department of Internal Medicine, Seoul National University Boramae Medical Center, 20 Boramae-Ro-5-Gil, Dongjak-Gu, Seoul, 07061, Republic of Korea. gistmd74@snu.ac.kr.